PORTLAND, Ore.–(BUSINESS WIRE)–April 15, 2014–
DesignMedix, Inc., a biotech startup with ties to Portland State University, received a grant for almost $3 million from the National Institutes of Health to continue development and manufacture of a new anti-malarial drug.
“Each year, over 600,000 children under the age of five die of malaria,” said Dr. Sandra Shotwell, president and COO of DesignMedix. “Our new drug will provide another weapon to target this deadly disease, which kills more young children than any other.”
The drug in development is a low cost cure for drug-resistant malaria that is as safe as chloroquine, a frontline drug used for many years until rendered ineffective by drug resistance. Malaria drug resistance – widespread in Africa and Asia – is created by a mutation that causes rapid transport of the drug out of the malaria cells, rendering the drug ineffective. The DesignMedix technology approach creates a new drug that inhibits the transport and overcomes the drug resistance.
DesignMedix will share the three-year grant with the chemistry lab of PSU professor David Peyton, who invented the technology and co-founded the company. Three patents have been issued relating to the drug molecules, and DesignMedix has exclusive rights to develop the technology.
“I am very pleased that NIH has continued to support this work in such a significant way,” said Peyton, who has been working on malaria for more than 15 years.
Several malaria drugs currently are available from large multinational and Indian drug manufacturers. Most current therapies show drug resistance, and some cost up to tenfold more than the cost projected for DesignMedix’s drug. This drug has high potential to be a good partner drug for existing or pipeline malaria drugs to both overcome drug resistance, and reduce cost. DesignMedix has partnered with Oregon Consultants Inc. (OCI) of Eugene, Oregon to produce material for preclinical and clinical studies.
About DesignMedix, Inc.
DesignMedix, Inc. was founded in 2008 to develop drugs to overcome drug resistance. The company’s initial focus is on oral drugs to treat malaria, which kills over 600,000 people per year and affects up to 500 million people. The company has developed a series of novel, safe and effective drugs that have the potential for low-cost production. For more information please visit http://www.designmedix.com.
The Advanced Technology Phase II award from the National Institute of Allergy and Infectious Diseases (NIAID) is part of the Small Business Technology Transfer Program of the NIH. Research reported in this release is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, under Award Number R41AI094959. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Sandra Shotwell, Ph.D., President and COO
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more